findmyKOL
Clinical trialNCT02165202CompletedPhase 2Interventional

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

SponsorPATHEnrollment136Human Immunodeficiency Virus (HIV)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Africa
  • Emavundleni Clinical Research Site

    Cape Town, South Africa

United States
  • New Jersey Medical School Clinical Research Center

    Newark, New Jersey, United States

  • Bronx Prevention Center

    The Bronx, New York, United States

Zimbabwe
  • Spilhaus Clinical Research Site

    Belgravia, Harare, Zimbabwe

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2014
Primary completion
13 Apr 2015
Completion
9 Mar 2017
Last update posted
27 Aug 2018
Registered enrollment
136
Registry id
NCT02165202
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.